Cargando…
Evaluation of real-world early response of DMO to aflibercept therapy to inform future clinical trial design of novel investigational agents
New clinical trials for diabetic macular oedema (DMO) are being designed to prove superiority over aflibercept when this agent is already very effective in improving visual acuity (VA) and DMO. The aim of this study was to determine the optimal inclusion–exclusion criteria for trials to aim for supe...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536417/ https://www.ncbi.nlm.nih.gov/pubmed/33020570 http://dx.doi.org/10.1038/s41598-020-73571-6 |